TRAIL-induced caspase/p38 activation is responsible for the increased catalytic and invasive activities of Akt

International Journal of Oncology

Volumn 38, Issue 1, 2011, Pages 249-256

  Sun, Bo K ^a   Kim, Joo Hang ^a,b   Nguyen, Hoan N ^d   Kim, So Y ^a,b   Oh, Seeun ^a,b   Lee, Yong J ^c   Song, Jae J ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

Akt catalytic activity; HSP27; Invasion; p38; TRAIL

Indexed keywords

CASPASE 8; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CATALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HOMEOSTASIS; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

CASPASES; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 78650830551     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000845     Document Type: Article

References (50)

1. Zhu H, Zhang L, Huang X, Davis JJ, Jacob DA, Teraishi F, Chiao P and Fang B: Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 9: 666-673, 2004. (Pubitemid 38660419)
2. Zhang L and Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237, 2005.
3. Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V, Forti G, Capitani S and Zauli G: TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61: 1965-1974, 2004.
4. Morel J, Audo R, Hahne M and Combe B: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 280: 15709-15718, 2005.
5. Zauli G, Sancilio S, Cataldi A, Sabatini N, Bosco D and Di Pietro R: PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment. J Cell Physiol 202: 900-911, 2005. (Pubitemid 40175868)
6. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, Emme D, Röder C, Kalthoff H and Wajant H: TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25: 7434-7439, 2006.
7. Song JJ, An JY, Kwon YT and Lee YJ: Evidence for two modes of development of acquired TRAIL resistance: Involvement of Bcl-xL. J Biol Chem 282: 319-328, 2007.
8. Brinckerhoff CE, Rutter JL and Benbow U: Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6: 4823-4830, 2000.
9. Freije JM, Díez-Itza I, Balbín M, Sánchez LM, Blasco R, Tolivia J and López-Otín C: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269: 16766-16773, 1994.
10. Johansson N, Airola K, Grénman R, Kariniemi AL, Saarialho-Kere U and Kähäri VM: Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 151: 499-508, 1997.
11. Uría JA, Balbín M, López JM, Alvarez J, Vizoso F, Takigawa M and López-Otín C: Collagenase-3 (MMP-13) expression in squamous cell carcinomas of the head and neck. Am J Pathol 153: 91-101, 1998.
12. Bostrom PJ, Ravanti L, Reunanen N, Aaltonen V, Söderström KO, Kähäri VM and Laato M: Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder. Int J Cancer 88: 417-423, 2000.
13. Lu Y, Xial G, Galson DL, Nishio Y, Mizokami A, Keller ET, Yao Z and Zhang J: PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro. Int J Cancer 121: 724-733, 2007.
14. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z and Zhang J: Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66: 1311-1318, 2006. (Pubitemid 44384308)
15. Song JJ, Kim JH, Sun BK, Alcala Jr MA, Bartlett DL and Lee YJ: c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment. Cell Signal 22: 377-385, 2010.
16. Song JJ and Lee YJ: Dissociation of Akt1 from its negative regulator JIP1 is mediated through the ASK1-MEK-JNK signal transduction pathway during metabolic oxidative stress: a negative feedback loop. J Cell Biol 170: 61-72, 2005.
17. Song JJ and Lee YJ: Differential cleavage of Mst1 by caspase-3/-7 is responsible for TRAIL-induced activation of the MAPK superfamily. Cell Signal 20: 892-906, 2008.
18. Leppä S and Bohmann D: Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 18: 6158-6162, 1999.
19. Matsuzawa A and Ichijo H: Molecular mechanisms of the decision between life and death: regulation of apoptosis by apoptosis signal-regulating kinase 1. J Biochem 130: 1-8, 2001.
20. Liu J and Lin A: Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15: 36-42, 2005.
21. Roulston A, Reinhard C, Amiri P and Williams LT: Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem 273: 10232-10239, 1998.
22. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278: 19245-19256, 2003.
23. Luo Y and DeFranco DB: Opposing roles for ERK1/2 in neuronal oxidative toxicity: distinct mechanisms of ERK1/2 action at early versus late phases of oxidative stress. J Biol Chem 281: 16436-16442, 2006. (Pubitemid 43909594)
24. Zheng C, Lin Z, Zhao ZJ, Yang Y, Niu H and Shen X: MAPK-activated protein kinase-2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex consisting of p38, MK2, Akt, and Hsp27. J Biol Chem 281: 37215-37226, 2006.
25. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T and Nebreda AR: A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78: 1027-1037, 1994.
26. Garrido C: Size matters: of the small HSP27 and its large oligomers. Cell Death Differ 9: 483-485, 2002.
27. Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, Paul C, Wieske M, Arrigo AP, Buchner J and Gaestel M: Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem 274: 18947-18956, 1999.
28. Stokoe D, Engel K, Campbell DG, Cohen P and Gaestel M: Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins. FEBS Lett 313: 307-313, 1992.
29. Xu L, Chen S and Bergan RC: MAPKAPK2 and HSP27 are downstream effectors of p38MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 25: 2987-2998, 2006. (Pubitemid 43780463)
30. Shankar S, Ganapathy S, Chen Q and Srivastava RK: Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 7: 16-28, 2008.
31. Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A and Ford HL: Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 67: 3036-3042, 2007.
32. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D and Ashkenazi A: Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280: 40599-40608, 2005.
33. Song JJ, Szczepanski MJ, Kim SY, Kim JH, An JY, Kwon YT, Alcala Jr MA, Bartlett DL and Lee YJ: c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. Cell Signal 22: 553-563, 2010.
34. Fan Y and Bergmann A: Apoptosis-induced compensatory proliferation. The Cell is dead. Long live the Cell! Trends Cell Biol 18: 467-473, 2008.
35. Franke TF, Kaplan DR and Cantley LC: PI3K: downstream AKTion blocks apoptosis. Cell 88: 435-437, 1997.
36. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
37. Hajduch E, Litherland GJ and Hundal HS: Protein kinase B (PKB/Akt)-a key regulator of glucose transport? FEBS Lett 492: 199-203, 2001.
38. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999.
39. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321, 1998.
40. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997. (Pubitemid 27456390)
41. Hetman M, Cavanaugh JE, Kimelman D and Xia Z: Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci 20: 2567-2574, 2000.
42. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL and Burgering BM: Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398: 630-634, 1999.
43. Pap M and Cooper GM: Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932, 1998.
44. Zhao Y, Zhao X, Yang B, Neuzil J and Wu K: alpha-Tocopheryl succinate-induced apoptosis in human gastric cancer cells is modulated by ERK1/2 and c-Jun N-terminal kinase in a biphasic manner. Cancer Lett 247: 345-352, 2007.
45. Lüschen S, Scherer G, Ussat S, Ungefroren H and Adam-Klages S: Inhibition of p38 mitogen-activated protein kinase reduces TNF-induced activation of NF-kappaB, elicits caspase activity, and enhances cytotoxicity. Exp Cell Res 293: 196-206, 2004.
46. Bradham C and McClay DR: p38 MAPK in development and cancer. Cell Cycle 5: 824-828, 2006.
47. Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549, 2009.
48. Junttila MR, Ala-Aho R, Jokilehto T, Peltonen J, Kallajoki M, Grenman R, Jaakkola P, Westermarck J and Kähäri VM: p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 26: 5267-5279, 2007.
49. Ricote M, García-Tuñín I, Fraile B, Fernández C, Aller P, Paniagua R and Royuela M: p38 MAPK protects against TNFalpha-provoked apoptosis in LNCaP prostatic cancer cells. Apoptosis 11: 1969-1975, 2006.
50. Hui L, Bakiri L, Stepniak E and Wagner EF: p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 6: 2429-2433, 2007. (Pubitemid 350058657)